Search

Your search keyword '"Misale, Sandra"' showing total 228 results
Start Over Author "Misale, Sandra"
228 results on '"Misale, Sandra"'

1. The 2023 generation

Author

Achinger-Kawecka, Joanna, Correa, Santiago, Hu, Jing, Li, Gaopeng, Lindeboom, Rik G. H., Misale, Sandra, Monkkonen, Teresa, Nirmal, Ajit J., Prekovic, Stefan, Sinha, Sanju, Trigos, Anna S., and Watson, Caroline J.

Published
2023
Full Text
View/download PDF

3. Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy

Author

Di Pilato, Mauro, Kim, Edward Y, Cadilha, Bruno L, Prüßmann, Jasper N, Nasrallah, Mazen N, Seruggia, Davide, Usmani, Shariq M, Misale, Sandra, Zappulli, Valentina, Carrizosa, Esteban, Mani, Vinidhra, Ligorio, Matteo, Warner, Ross D, Medoff, Benjamin D, Marangoni, Francesco, Villani, Alexandra-Chloe, and Mempel, Thorsten R

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Genetics, 2.1 Biological and endogenous factors, Aetiology, Cancer, Animals, Autoimmunity, B-Cell CLL-Lymphoma 10 Protein, B7-H1 Antigen, CARD Signaling Adaptor Proteins, Female, Immune Tolerance, Immunotherapy, Interferon-gamma, Macrophages, Male, Mice, Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein, Multiprotein Complexes, Neoplasms, T-Lymphocytes, Regulatory, General Science & Technology
Abstract

Solid tumours are infiltrated by effector T cells with the potential to control or reject them, as well as by regulatory T (Treg) cells that restrict the function of effector T cells and thereby promote tumour growth1. The anti-tumour activity of effector T cells can be therapeutically unleashed, and is now being exploited for the treatment of some forms of human cancer. However, weak tumour-associated inflammatory responses and the immune-suppressive function of Treg cells remain major hurdles to broader effectiveness of tumour immunotherapy2. Here we show that, after disruption of the CARMA1-BCL10-MALT1 (CBM) signalosome complex, most tumour-infiltrating Treg cells produce IFNγ, resulting in stunted tumour growth. Notably, genetic deletion of both or even just one allele of CARMA1 (also known as Card11) in only a fraction of Treg cells-which avoided systemic autoimmunity-was sufficient to produce this anti-tumour effect, showing that it is not the mere loss of suppressive function but the gain of effector activity by Treg cells that initiates tumour control. The production of IFNγ by Treg cells was accompanied by activation of macrophages and upregulation of class I molecules of the major histocompatibility complex on tumour cells. However, tumour cells also upregulated the expression of PD-L1, which indicates activation of adaptive immune resistance3. Consequently, blockade of PD-1 together with CARMA1 deletion caused rejection of tumours that otherwise do not respond to anti-PD-1 monotherapy. This effect was reproduced by pharmacological inhibition of the CBM protein MALT1. Our results demonstrate that partial disruption of the CBM complex and induction of IFNγ secretion in the preferentially self-reactive Treg cell pool does not cause systemic autoimmunity but is sufficient to prime the tumour environment for successful immune checkpoint therapy.

Published
2019

4. Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer

Author

Ligorio, Matteo, Sil, Srinjoy, Malagon-Lopez, Jose, Nieman, Linda T, Misale, Sandra, Di Pilato, Mauro, Ebright, Richard Y, Karabacak, Murat N, Kulkarni, Anupriya S, Liu, Ann, Vincent Jordan, Nicole, Franses, Joseph W, Philipp, Julia, Kreuzer, Johannes, Desai, Niyati, Arora, Kshitij S, Rajurkar, Mihir, Horwitz, Elad, Neyaz, Azfar, Tai, Eric, Magnus, Neelima KC, Vo, Kevin D, Yashaswini, Chittampalli N, Marangoni, Francesco, Boukhali, Myriam, Fatherree, Jackson P, Damon, Leah J, Xega, Kristina, Desai, Rushil, Choz, Melissa, Bersani, Francesca, Langenbucher, Adam, Thapar, Vishal, Morris, Robert, Wellner, Ulrich F, Schilling, Oliver, Lawrence, Michael S, Liss, Andrew S, Rivera, Miguel N, Deshpande, Vikram, Benes, Cyril H, Maheswaran, Shyamala, Haber, Daniel A, Fernandez-Del-Castillo, Carlos, Ferrone, Cristina R, Haas, Wilhelm, Aryee, Martin J, and Ting, David T

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biological Sciences, Rare Diseases, Genetics, Digestive Diseases, Stem Cell Research, Pancreatic Cancer, Cancer, Stem Cell Research - Nonembryonic - Human, 2.1 Biological and endogenous factors, Aetiology, Animals, Cancer-Associated Fibroblasts, Carcinoma, Pancreatic Ductal, Cell Proliferation, Coculture Techniques, Epithelial-Mesenchymal Transition, Female, HEK293 Cells, Heterografts, Humans, Mice, Mice, Inbred NOD, Mice, SCID, Mitogen-Activated Protein Kinases, Pancreatic Neoplasms, RNA-Seq, STAT3 Transcription Factor, Stromal Cells, Transfection, Tumor Microenvironment, mass spectrometry, pancreatic cancer, pancreatic ductal adenocarcinoma, single cell RNA-sequencing, single cell spatial analysis, stromal microenvironment, tumor architecture, Medical and Health Sciences, Developmental Biology, Biological sciences, Biomedical and clinical sciences
Abstract

Single-cell technologies have described heterogeneity across tissues, but the spatial distribution and forces that drive single-cell phenotypes have not been well defined. Combining single-cell RNA and protein analytics in studying the role of stromal cancer-associated fibroblasts (CAFs) in modulating heterogeneity in pancreatic cancer (pancreatic ductal adenocarcinoma [PDAC]) model systems, we have identified significant single-cell population shifts toward invasive epithelial-to-mesenchymal transition (EMT) and proliferative (PRO) phenotypes linked with mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3) signaling. Using high-content digital imaging of RNA in situ hybridization in 195 PDAC tumors, we quantified these EMT and PRO subpopulations in 319,626 individual cancer cells that can be classified within the context of distinct tumor gland "units." Tumor gland typing provided an additional layer of intratumoral heterogeneity that was associated with differences in stromal abundance and clinical outcomes. This demonstrates the impact of the stroma in shaping tumor architecture by altering inherent patterns of tumor glands in human PDAC.

Published
2019

5. Anatomic position determines oncogenic specificity in melanoma

Author

Weiss, Joshua M., Hunter, Miranda V., Cruz, Nelly M., Baggiolini, Arianna, Tagore, Mohita, Ma, Yilun, Misale, Sandra, Marasco, Michelangelo, Simon-Vermot, Theresa, Campbell, Nathaniel R., Newell, Felicity, Wilmott, James S., Johansson, Peter A., Thompson, John F., Long, Georgina V., Pearson, John V., Mann, Graham J., Scolyer, Richard A., Waddell, Nicola, Montal, Emily D., Huang, Ting-Hsiang, Jonsson, Philip, Donoghue, Mark T. A., Harris, Christopher C., Taylor, Barry S., Xu, Tianhao, Chaligné, Ronan, Shliaha, Pavel V., Hendrickson, Ronald, Jungbluth, Achim A., Lezcano, Cecilia, Koche, Richard, Studer, Lorenz, Ariyan, Charlotte E., Solit, David B., Wolchok, Jedd D., Merghoub, Taha, Rosen, Neal, Hayward, Nicholas K., and White, Richard M.

Published
2022
Full Text
View/download PDF

8. Resistance to TRK inhibition mediated by convergent MAPK pathway activation

Author

Cocco, Emiliano, Schram, Alison M., Kulick, Amanda, Misale, Sandra, Won, Helen H., Yaeger, Rona, and Razavi, Pedram

Subjects
Biological sciences, Health
Abstract

TRK fusions are found in a variety of cancer types, lead to oncogenic addiction, and strongly predict tumor-agnostic efficacy of TRK inhibition.sup.1-8. With the recent approval of the first selective TRK inhibitor, larotrectinib, for patients with any TRK-fusion-positive adult or pediatric solid tumor, to identify mechanisms of treatment failure after initial response has become of immediate therapeutic relevance. So far, the only known resistance mechanism is the acquisition of on-target TRK kinase domain mutations, which interfere with drug binding and can potentially be addressable through second-generation TRK inhibitors.sup.9-11. Here, we report off-target resistance in patients treated with TRK inhibitors and in patient-derived models, mediated by genomic alterations that converge to activate the mitogen-activated protein kinase (MAPK) pathway. MAPK pathway-directed targeted therapy, administered alone or in combination with TRK inhibition, re-established disease control. Experimental modeling further suggests that upfront dual inhibition of TRK and MEK may delay time to progression in cancer types prone to the genomic acquisition of MAPK pathway-activating alterations. Collectively, these data suggest that a subset of patients will develop off-target mechanisms of resistance to TRK inhibition with potential implications for clinical management and future clinical trial design. A subset of patients treated with selective TRK inhibitors (including the newly approved larotrectinib) develop off-target resistance mediated by genomic acquisition of MAPK pathway-activating alterations, and may benefit from combined targeted therapy., Author(s): Emiliano Cocco [sup.1] [sup.2] , Alison M. Schram [sup.3] [sup.4] , Amanda Kulick [sup.5] [sup.6] , Sandra Misale [sup.5] , Helen H. Won [sup.7] , Rona Yaeger [sup.3] [sup.5] [...]

Published
2019
Full Text
View/download PDF

9. Supplementary Table 1 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Author

Yaeger, Rona, primary, Mezzadra, Riccardo, primary, Sinopoli, Jenna, primary, Bian, Yu, primary, Marasco, Michelangelo, primary, Kaplun, Esther, primary, Gao, Yijun, primary, Zhao, HuiYong, primary, Paula, Arnaud Da Cruz, primary, Zhu, Yingjie, primary, Perez, Almudena Chaves, primary, Chadalavada, Kalyani, primary, Tse, Edison, primary, Chowdhry, Sudhir, primary, Bowker, Sydney, primary, Chang, Qing, primary, Qeriqi, Besnik, primary, Weigelt, Britta, primary, Nanjangud, Gouri J., primary, Berger, Michael F., primary, Der-Torossian, Hirak, primary, Anderes, Kenna, primary, Socci, Nicholas D., primary, Shia, Jinru, primary, Riely, Gregory J., primary, Murciano-Goroff, Yonina R., primary, Li, Bob T., primary, Christensen, James G., primary, Reis-Filho, Jorge S., primary, Solit, David B., primary, de Stanchina, Elisa, primary, Lowe, Scott W., primary, Rosen, Neal, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Author

Yaeger, Rona, primary, Mezzadra, Riccardo, primary, Sinopoli, Jenna, primary, Bian, Yu, primary, Marasco, Michelangelo, primary, Kaplun, Esther, primary, Gao, Yijun, primary, Zhao, HuiYong, primary, Paula, Arnaud Da Cruz, primary, Zhu, Yingjie, primary, Perez, Almudena Chaves, primary, Chadalavada, Kalyani, primary, Tse, Edison, primary, Chowdhry, Sudhir, primary, Bowker, Sydney, primary, Chang, Qing, primary, Qeriqi, Besnik, primary, Weigelt, Britta, primary, Nanjangud, Gouri J., primary, Berger, Michael F., primary, Der-Torossian, Hirak, primary, Anderes, Kenna, primary, Socci, Nicholas D., primary, Shia, Jinru, primary, Riely, Gregory J., primary, Murciano-Goroff, Yonina R., primary, Li, Bob T., primary, Christensen, James G., primary, Reis-Filho, Jorge S., primary, Solit, David B., primary, de Stanchina, Elisa, primary, Lowe, Scott W., primary, Rosen, Neal, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Author

Yaeger, Rona, primary, Mezzadra, Riccardo, primary, Sinopoli, Jenna, primary, Bian, Yu, primary, Marasco, Michelangelo, primary, Kaplun, Esther, primary, Gao, Yijun, primary, Zhao, HuiYong, primary, Paula, Arnaud Da Cruz, primary, Zhu, Yingjie, primary, Perez, Almudena Chaves, primary, Chadalavada, Kalyani, primary, Tse, Edison, primary, Chowdhry, Sudhir, primary, Bowker, Sydney, primary, Chang, Qing, primary, Qeriqi, Besnik, primary, Weigelt, Britta, primary, Nanjangud, Gouri J., primary, Berger, Michael F., primary, Der-Torossian, Hirak, primary, Anderes, Kenna, primary, Socci, Nicholas D., primary, Shia, Jinru, primary, Riely, Gregory J., primary, Murciano-Goroff, Yonina R., primary, Li, Bob T., primary, Christensen, James G., primary, Reis-Filho, Jorge S., primary, Solit, David B., primary, de Stanchina, Elisa, primary, Lowe, Scott W., primary, Rosen, Neal, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 3 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Author

Yaeger, Rona, primary, Mezzadra, Riccardo, primary, Sinopoli, Jenna, primary, Bian, Yu, primary, Marasco, Michelangelo, primary, Kaplun, Esther, primary, Gao, Yijun, primary, Zhao, HuiYong, primary, Paula, Arnaud Da Cruz, primary, Zhu, Yingjie, primary, Perez, Almudena Chaves, primary, Chadalavada, Kalyani, primary, Tse, Edison, primary, Chowdhry, Sudhir, primary, Bowker, Sydney, primary, Chang, Qing, primary, Qeriqi, Besnik, primary, Weigelt, Britta, primary, Nanjangud, Gouri J., primary, Berger, Michael F., primary, Der-Torossian, Hirak, primary, Anderes, Kenna, primary, Socci, Nicholas D., primary, Shia, Jinru, primary, Riely, Gregory J., primary, Murciano-Goroff, Yonina R., primary, Li, Bob T., primary, Christensen, James G., primary, Reis-Filho, Jorge S., primary, Solit, David B., primary, de Stanchina, Elisa, primary, Lowe, Scott W., primary, Rosen, Neal, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Author

Yaeger, Rona, primary, Mezzadra, Riccardo, primary, Sinopoli, Jenna, primary, Bian, Yu, primary, Marasco, Michelangelo, primary, Kaplun, Esther, primary, Gao, Yijun, primary, Zhao, HuiYong, primary, Paula, Arnaud Da Cruz, primary, Zhu, Yingjie, primary, Perez, Almudena Chaves, primary, Chadalavada, Kalyani, primary, Tse, Edison, primary, Chowdhry, Sudhir, primary, Bowker, Sydney, primary, Chang, Qing, primary, Qeriqi, Besnik, primary, Weigelt, Britta, primary, Nanjangud, Gouri J., primary, Berger, Michael F., primary, Der-Torossian, Hirak, primary, Anderes, Kenna, primary, Socci, Nicholas D., primary, Shia, Jinru, primary, Riely, Gregory J., primary, Murciano-Goroff, Yonina R., primary, Li, Bob T., primary, Christensen, James G., primary, Reis-Filho, Jorge S., primary, Solit, David B., primary, de Stanchina, Elisa, primary, Lowe, Scott W., primary, Rosen, Neal, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Author

Yaeger, Rona, primary, Mezzadra, Riccardo, primary, Sinopoli, Jenna, primary, Bian, Yu, primary, Marasco, Michelangelo, primary, Kaplun, Esther, primary, Gao, Yijun, primary, Zhao, HuiYong, primary, Paula, Arnaud Da Cruz, primary, Zhu, Yingjie, primary, Perez, Almudena Chaves, primary, Chadalavada, Kalyani, primary, Tse, Edison, primary, Chowdhry, Sudhir, primary, Bowker, Sydney, primary, Chang, Qing, primary, Qeriqi, Besnik, primary, Weigelt, Britta, primary, Nanjangud, Gouri J., primary, Berger, Michael F., primary, Der-Torossian, Hirak, primary, Anderes, Kenna, primary, Socci, Nicholas D., primary, Shia, Jinru, primary, Riely, Gregory J., primary, Murciano-Goroff, Yonina R., primary, Li, Bob T., primary, Christensen, James G., primary, Reis-Filho, Jorge S., primary, Solit, David B., primary, de Stanchina, Elisa, primary, Lowe, Scott W., primary, Rosen, Neal, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Author

Yaeger, Rona, primary, Mezzadra, Riccardo, primary, Sinopoli, Jenna, primary, Bian, Yu, primary, Marasco, Michelangelo, primary, Kaplun, Esther, primary, Gao, Yijun, primary, Zhao, HuiYong, primary, Paula, Arnaud Da Cruz, primary, Zhu, Yingjie, primary, Perez, Almudena Chaves, primary, Chadalavada, Kalyani, primary, Tse, Edison, primary, Chowdhry, Sudhir, primary, Bowker, Sydney, primary, Chang, Qing, primary, Qeriqi, Besnik, primary, Weigelt, Britta, primary, Nanjangud, Gouri J., primary, Berger, Michael F., primary, Der-Torossian, Hirak, primary, Anderes, Kenna, primary, Socci, Nicholas D., primary, Shia, Jinru, primary, Riely, Gregory J., primary, Murciano-Goroff, Yonina R., primary, Li, Bob T., primary, Christensen, James G., primary, Reis-Filho, Jorge S., primary, Solit, David B., primary, de Stanchina, Elisa, primary, Lowe, Scott W., primary, Rosen, Neal, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Author

Yaeger, Rona, primary, Mezzadra, Riccardo, primary, Sinopoli, Jenna, primary, Bian, Yu, primary, Marasco, Michelangelo, primary, Kaplun, Esther, primary, Gao, Yijun, primary, Zhao, HuiYong, primary, Paula, Arnaud Da Cruz, primary, Zhu, Yingjie, primary, Perez, Almudena Chaves, primary, Chadalavada, Kalyani, primary, Tse, Edison, primary, Chowdhry, Sudhir, primary, Bowker, Sydney, primary, Chang, Qing, primary, Qeriqi, Besnik, primary, Weigelt, Britta, primary, Nanjangud, Gouri J., primary, Berger, Michael F., primary, Der-Torossian, Hirak, primary, Anderes, Kenna, primary, Socci, Nicholas D., primary, Shia, Jinru, primary, Riely, Gregory J., primary, Murciano-Goroff, Yonina R., primary, Li, Bob T., primary, Christensen, James G., primary, Reis-Filho, Jorge S., primary, Solit, David B., primary, de Stanchina, Elisa, primary, Lowe, Scott W., primary, Rosen, Neal, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

19. Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.

Author

Rustgi, Naryan, Maria, Ann, Toumbacaris, Nicolas, Zhao, HuiYong, Kargus, Katherine, Bryant, Morgan, Waksmundzki, Alexandra, Aricescu, Ilinca, Lefkowitz, Robert A, Li, Bob T, Chou, Joanne, Capanu, Marinela, Stanchina, Elisa de, Misale, Sandra, Shia, Jinru, and Yaeger, Rona

Subjects
RNA analysis, DNA analysis, TUMOR prevention, IN vitro studies, DRUG efficacy, GENETIC mutation, IN vivo studies, XENOGRAFTS, BIOPSY, CLINICAL trials, CONFIDENCE intervals, PROTEIN kinase inhibitors, CULTURE media (Biology), MONOCLONAL antibodies, HEALTH outcome assessment, REGRESSION analysis, IMMUNOBLOTTING, CELLULAR signal transduction, PHARMACEUTICAL arithmetic, CANCER genes, DESCRIPTIVE statistics, TUMORS, MITOGEN-activated protein kinases, CELL lines, PROGRESSION-free survival, MICE, PATIENT safety, OVERALL survival, CHEMICAL inhibitors
Abstract

Background Cancers with non-V600 BRAF-activating alterations have no matched therapy. Preclinical data suggest that these tumors depend on ERK signaling; however, clinical response to MEK/ERK inhibitors has overall been low. We hypothesized that a narrow therapeutic index, driven by ERK inhibition in healthy (wild-type) tissues, limits the efficacy of these inhibitors. As these mutants signal as activated dimers, we further hypothesized that RAF inhibitors given concurrently would improve the therapeutic index by opposing ERK inhibition in normal tissues and not activate ERK in the already activated tumor. Materials and Methods Using cell lines and patient-derived xenografts, we evaluated the effect of RAF inhibition, alone and in combination with MEK/ERK inhibitors. We then undertook a phase I/II clinical trial of a higher dose of the MEK inhibitor binimetinib combined with the RAF inhibitor encorafenib in patients with advanced cancer with activating non-V600 BRAF alterations. Results RAF inhibition led to modest inhibition of signaling and growth in activated non-V600 BRAF preclinical models and allowed higher dose of MEK/ERK inhibitors in vivo for more profound tumor regression. Fifteen patients received binimetinib 60 mg twice daily plus encorafenib 450 mg daily (6 gastrointestinal primaries, 6 genitourinary primaries, 3 melanoma, and 2 lung cancer; 7 BRAF mutations and 8 BRAF fusions). Treatment was well tolerated without dose-limiting toxicities. One patient had a confirmed partial response, 8 had stable disease, and 6 had radiographic or clinical progression as best response. On-treatment biopsies revealed incomplete ERK pathway inhibition. Conclusion Combined RAF and MEK inhibition does not sufficiently inhibit activated non-V600 BRAF-mutant tumors in patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Abstract 2: Vertical MAPK pathway targeting in novel genetically engineered mouse and cell line models of NF1-altered melanoma: the mSK-Mel murine cohort

Author

Jones, Alexis M., primary, Hanrahan, Aphrothiti J., additional, Nissan, Moriah H., additional, Monette, Sebastien, additional, Chen, Ziyu, additional, Hu, Wenhuo, additional, Misale, Sandra, additional, Schulze, Isabell, additional, Vasani, Naresh, additional, Liu, Cailian, additional, Yang, Xia, additional, Abu-Akeel, Mohsen, additional, de Stanchina, Elisa, additional, Schultz, Nikolaus, additional, Berger, Michael F., additional, Rosen, Neal, additional, Merghoub, Taha, additional, and Solit, David B., additional

Published
2023
Full Text
View/download PDF

22. Supplementary Table 3 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Author

Yaeger, Rona, primary, Mezzadra, Riccardo, primary, Sinopoli, Jenna, primary, Bian, Yu, primary, Marasco, Michelangelo, primary, Kaplun, Esther, primary, Gao, Yijun, primary, Zhao, HuiYong, primary, Paula, Arnaud Da Cruz, primary, Zhu, Yingjie, primary, Perez, Almudena Chaves, primary, Chadalavada, Kalyani, primary, Tse, Edison, primary, Chowdhry, Sudhir, primary, Bowker, Sydney, primary, Chang, Qing, primary, Qeriqi, Besnik, primary, Weigelt, Britta, primary, Nanjangud, Gouri J., primary, Berger, Michael F., primary, Der-Torossian, Hirak, primary, Anderes, Kenna, primary, Socci, Nicholas D., primary, Shia, Jinru, primary, Riely, Gregory J., primary, Murciano-Goroff, Yonina R., primary, Li, Bob T., primary, Christensen, James G., primary, Reis-Filho, Jorge S., primary, Solit, David B., primary, de Stanchina, Elisa, primary, Lowe, Scott W., primary, Rosen, Neal, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

23. Data from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Author

Yaeger, Rona, primary, Mezzadra, Riccardo, primary, Sinopoli, Jenna, primary, Bian, Yu, primary, Marasco, Michelangelo, primary, Kaplun, Esther, primary, Gao, Yijun, primary, Zhao, HuiYong, primary, Paula, Arnaud Da Cruz, primary, Zhu, Yingjie, primary, Perez, Almudena Chaves, primary, Chadalavada, Kalyani, primary, Tse, Edison, primary, Chowdhry, Sudhir, primary, Bowker, Sydney, primary, Chang, Qing, primary, Qeriqi, Besnik, primary, Weigelt, Britta, primary, Nanjangud, Gouri J., primary, Berger, Michael F., primary, Der-Torossian, Hirak, primary, Anderes, Kenna, primary, Socci, Nicholas D., primary, Shia, Jinru, primary, Riely, Gregory J., primary, Murciano-Goroff, Yonina R., primary, Li, Bob T., primary, Christensen, James G., primary, Reis-Filho, Jorge S., primary, Solit, David B., primary, de Stanchina, Elisa, primary, Lowe, Scott W., primary, Rosen, Neal, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 3 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Author

Amodio, Vito, primary, Yaeger, Rona, primary, Arcella, Pamela, primary, Cancelliere, Carlotta, primary, Lamba, Simona, primary, Lorenzato, Annalisa, primary, Arena, Sabrina, primary, Montone, Monica, primary, Mussolin, Benedetta, primary, Bian, Yu, primary, Whaley, Adele, primary, Pinnelli, Marika, primary, Murciano-Goroff, Yonina R., primary, Vakiani, Efsevia, primary, Valeri, Nicola, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Thyparambil, Sheeno, primary, Zhao, Hui-Yong, primary, de Stanchina, Elisa, primary, Marsoni, Silvia, primary, Siena, Salvatore, primary, Bertotti, Andrea, primary, Trusolino, Livio, primary, Li, Bob T., primary, Rosen, Neal, primary, Di Nicolantonio, Federica, primary, Bardelli, Alberto, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

27. Data from TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

Author

Cocco, Emiliano, primary, Lee, Ji Eun, primary, Kannan, Srinivasaraghavan, primary, Schram, Alison M., primary, Won, Helen H., primary, Shifman, Sophie, primary, Kulick, Amanda, primary, Baldino, Laura, primary, Toska, Eneda, primary, Arruabarrena-Aristorena, Amaia, primary, Kittane, Srushti, primary, Wu, Fan, primary, Cai, Yanyan, primary, Arena, Sabrina, primary, Mussolin, Benedetta, primary, Kannan, Ram, primary, Vasan, Neil, primary, Gorelick, Alexander N., primary, Berger, Michael F., primary, Novoplansky, Ofra, primary, Jagadeeshan, Sankar, primary, Liao, Yi, primary, Rix, Uwe, primary, Misale, Sandra, primary, Taylor, Barry S., primary, Bardelli, Alberto, primary, Hechtman, Jaclyn F., primary, Hyman, David M., primary, Elkabets, Moshe, primary, de Stanchina, Elisa, primary, Verma, Chandra S., primary, Ventura, Andrea, primary, Drilon, Alexander, primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table 2 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Author

Amodio, Vito, primary, Yaeger, Rona, primary, Arcella, Pamela, primary, Cancelliere, Carlotta, primary, Lamba, Simona, primary, Lorenzato, Annalisa, primary, Arena, Sabrina, primary, Montone, Monica, primary, Mussolin, Benedetta, primary, Bian, Yu, primary, Whaley, Adele, primary, Pinnelli, Marika, primary, Murciano-Goroff, Yonina R., primary, Vakiani, Efsevia, primary, Valeri, Nicola, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Thyparambil, Sheeno, primary, Zhao, Hui-Yong, primary, de Stanchina, Elisa, primary, Marsoni, Silvia, primary, Siena, Salvatore, primary, Bertotti, Andrea, primary, Trusolino, Livio, primary, Li, Bob T., primary, Rosen, Neal, primary, Di Nicolantonio, Federica, primary, Bardelli, Alberto, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

29. Data from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 1 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

31. Data from Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer

Author

Russo, Mariangela, primary, Misale, Sandra, primary, Wei, Ge, primary, Siravegna, Giulia, primary, Crisafulli, Giovanni, primary, Lazzari, Luca, primary, Corti, Giorgio, primary, Rospo, Giuseppe, primary, Novara, Luca, primary, Mussolin, Benedetta, primary, Bartolini, Alice, primary, Cam, Nicholas, primary, Patel, Roopal, primary, Yan, Shunqi, primary, Shoemaker, Robert, primary, Wild, Robert, primary, Di Nicolantonio, Federica, primary, Bianchi, Andrea Sartore, primary, Li, Gang, primary, Siena, Salvatore, primary, and Bardelli, Alberto, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 2 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Author

Amodio, Vito, primary, Yaeger, Rona, primary, Arcella, Pamela, primary, Cancelliere, Carlotta, primary, Lamba, Simona, primary, Lorenzato, Annalisa, primary, Arena, Sabrina, primary, Montone, Monica, primary, Mussolin, Benedetta, primary, Bian, Yu, primary, Whaley, Adele, primary, Pinnelli, Marika, primary, Murciano-Goroff, Yonina R., primary, Vakiani, Efsevia, primary, Valeri, Nicola, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Thyparambil, Sheeno, primary, Zhao, Hui-Yong, primary, de Stanchina, Elisa, primary, Marsoni, Silvia, primary, Siena, Salvatore, primary, Bertotti, Andrea, primary, Trusolino, Livio, primary, Li, Bob T., primary, Rosen, Neal, primary, Di Nicolantonio, Federica, primary, Bardelli, Alberto, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

33. Data from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Author

Amodio, Vito, primary, Yaeger, Rona, primary, Arcella, Pamela, primary, Cancelliere, Carlotta, primary, Lamba, Simona, primary, Lorenzato, Annalisa, primary, Arena, Sabrina, primary, Montone, Monica, primary, Mussolin, Benedetta, primary, Bian, Yu, primary, Whaley, Adele, primary, Pinnelli, Marika, primary, Murciano-Goroff, Yonina R., primary, Vakiani, Efsevia, primary, Valeri, Nicola, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Thyparambil, Sheeno, primary, Zhao, Hui-Yong, primary, de Stanchina, Elisa, primary, Marsoni, Silvia, primary, Siena, Salvatore, primary, Bertotti, Andrea, primary, Trusolino, Livio, primary, Li, Bob T., primary, Rosen, Neal, primary, Di Nicolantonio, Federica, primary, Bardelli, Alberto, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Fig 3 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 4 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Author

Amodio, Vito, primary, Yaeger, Rona, primary, Arcella, Pamela, primary, Cancelliere, Carlotta, primary, Lamba, Simona, primary, Lorenzato, Annalisa, primary, Arena, Sabrina, primary, Montone, Monica, primary, Mussolin, Benedetta, primary, Bian, Yu, primary, Whaley, Adele, primary, Pinnelli, Marika, primary, Murciano-Goroff, Yonina R., primary, Vakiani, Efsevia, primary, Valeri, Nicola, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Thyparambil, Sheeno, primary, Zhao, Hui-Yong, primary, de Stanchina, Elisa, primary, Marsoni, Silvia, primary, Siena, Salvatore, primary, Bertotti, Andrea, primary, Trusolino, Livio, primary, Li, Bob T., primary, Rosen, Neal, primary, Di Nicolantonio, Federica, primary, Bardelli, Alberto, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Methods, Figure Legends, Table Legends, Figures S1 - S4, Tables S1 - S5 from Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer

Author

Russo, Mariangela, primary, Misale, Sandra, primary, Wei, Ge, primary, Siravegna, Giulia, primary, Crisafulli, Giovanni, primary, Lazzari, Luca, primary, Corti, Giorgio, primary, Rospo, Giuseppe, primary, Novara, Luca, primary, Mussolin, Benedetta, primary, Bartolini, Alice, primary, Cam, Nicholas, primary, Patel, Roopal, primary, Yan, Shunqi, primary, Shoemaker, Robert, primary, Wild, Robert, primary, Di Nicolantonio, Federica, primary, Bianchi, Andrea Sartore, primary, Li, Gang, primary, Siena, Salvatore, primary, and Bardelli, Alberto, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Fig 1 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Fig 4 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Fig 6 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figures from TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

Author

Cocco, Emiliano, primary, Lee, Ji Eun, primary, Kannan, Srinivasaraghavan, primary, Schram, Alison M., primary, Won, Helen H., primary, Shifman, Sophie, primary, Kulick, Amanda, primary, Baldino, Laura, primary, Toska, Eneda, primary, Arruabarrena-Aristorena, Amaia, primary, Kittane, Srushti, primary, Wu, Fan, primary, Cai, Yanyan, primary, Arena, Sabrina, primary, Mussolin, Benedetta, primary, Kannan, Ram, primary, Vasan, Neil, primary, Gorelick, Alexander N., primary, Berger, Michael F., primary, Novoplansky, Ofra, primary, Jagadeeshan, Sankar, primary, Liao, Yi, primary, Rix, Uwe, primary, Misale, Sandra, primary, Taylor, Barry S., primary, Bardelli, Alberto, primary, Hechtman, Jaclyn F., primary, Hyman, David M., primary, Elkabets, Moshe, primary, de Stanchina, Elisa, primary, Verma, Chandra S., primary, Ventura, Andrea, primary, Drilon, Alexander, primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table 3 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Author

Amodio, Vito, primary, Yaeger, Rona, primary, Arcella, Pamela, primary, Cancelliere, Carlotta, primary, Lamba, Simona, primary, Lorenzato, Annalisa, primary, Arena, Sabrina, primary, Montone, Monica, primary, Mussolin, Benedetta, primary, Bian, Yu, primary, Whaley, Adele, primary, Pinnelli, Marika, primary, Murciano-Goroff, Yonina R., primary, Vakiani, Efsevia, primary, Valeri, Nicola, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Thyparambil, Sheeno, primary, Zhao, Hui-Yong, primary, de Stanchina, Elisa, primary, Marsoni, Silvia, primary, Siena, Salvatore, primary, Bertotti, Andrea, primary, Trusolino, Livio, primary, Li, Bob T., primary, Rosen, Neal, primary, Di Nicolantonio, Federica, primary, Bardelli, Alberto, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Fig 5 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table 1 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Author

Amodio, Vito, primary, Yaeger, Rona, primary, Arcella, Pamela, primary, Cancelliere, Carlotta, primary, Lamba, Simona, primary, Lorenzato, Annalisa, primary, Arena, Sabrina, primary, Montone, Monica, primary, Mussolin, Benedetta, primary, Bian, Yu, primary, Whaley, Adele, primary, Pinnelli, Marika, primary, Murciano-Goroff, Yonina R., primary, Vakiani, Efsevia, primary, Valeri, Nicola, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Thyparambil, Sheeno, primary, Zhao, Hui-Yong, primary, de Stanchina, Elisa, primary, Marsoni, Silvia, primary, Siena, Salvatore, primary, Bertotti, Andrea, primary, Trusolino, Livio, primary, Li, Bob T., primary, Rosen, Neal, primary, Di Nicolantonio, Federica, primary, Bardelli, Alberto, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 1 from EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Author

Amodio, Vito, primary, Yaeger, Rona, primary, Arcella, Pamela, primary, Cancelliere, Carlotta, primary, Lamba, Simona, primary, Lorenzato, Annalisa, primary, Arena, Sabrina, primary, Montone, Monica, primary, Mussolin, Benedetta, primary, Bian, Yu, primary, Whaley, Adele, primary, Pinnelli, Marika, primary, Murciano-Goroff, Yonina R., primary, Vakiani, Efsevia, primary, Valeri, Nicola, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Thyparambil, Sheeno, primary, Zhao, Hui-Yong, primary, de Stanchina, Elisa, primary, Marsoni, Silvia, primary, Siena, Salvatore, primary, Bertotti, Andrea, primary, Trusolino, Livio, primary, Li, Bob T., primary, Rosen, Neal, primary, Di Nicolantonio, Federica, primary, Bardelli, Alberto, primary, and Misale, Sandra, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Fig 2 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Tables from TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

Author

Cocco, Emiliano, primary, Lee, Ji Eun, primary, Kannan, Srinivasaraghavan, primary, Schram, Alison M., primary, Won, Helen H., primary, Shifman, Sophie, primary, Kulick, Amanda, primary, Baldino, Laura, primary, Toska, Eneda, primary, Arruabarrena-Aristorena, Amaia, primary, Kittane, Srushti, primary, Wu, Fan, primary, Cai, Yanyan, primary, Arena, Sabrina, primary, Mussolin, Benedetta, primary, Kannan, Ram, primary, Vasan, Neil, primary, Gorelick, Alexander N., primary, Berger, Michael F., primary, Novoplansky, Ofra, primary, Jagadeeshan, Sankar, primary, Liao, Yi, primary, Rix, Uwe, primary, Misale, Sandra, primary, Taylor, Barry S., primary, Bardelli, Alberto, primary, Hechtman, Jaclyn F., primary, Hyman, David M., primary, Elkabets, Moshe, primary, de Stanchina, Elisa, primary, Verma, Chandra S., primary, Ventura, Andrea, primary, Drilon, Alexander, primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figures from KRASG12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

Author

Jones, Gregory D., primary, Caso, Raul, primary, Tan, Kay See, primary, Mastrogiacomo, Brooke, primary, Sanchez-Vega, Francisco, primary, Liu, Yuan, primary, Connolly, James G., primary, Murciano-Goroff, Yonina R., primary, Bott, Matthew J., primary, Adusumilli, Prasad S., primary, Molena, Daniela, primary, Rocco, Gaetano, primary, Rusch, Valerie W., primary, Sihag, Smita, primary, Misale, Sandra, primary, Yaeger, Rona, primary, Drilon, Alexander, primary, Arbour, Kathryn C., primary, Riely, Gregory J., primary, Rosen, Neal, primary, Lito, Piro, primary, Zhang, Haiying, primary, Lyden, David C., primary, Rudin, Charles M., primary, Jones, David R., primary, Li, Bob T., primary, and Isbell, James M., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure S3 from Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer

Author

Arena, Sabrina, primary, Bellosillo, Beatriz, primary, Siravegna, Giulia, primary, Martínez, Alejandro, primary, Cañadas, Israel, primary, Lazzari, Luca, primary, Ferruz, Noelia, primary, Russo, Mariangela, primary, Misale, Sandra, primary, González, Iria, primary, Iglesias, Mar, primary, Gavilan, Elena, primary, Corti, Giorgio, primary, Hobor, Sebastijan, primary, Crisafulli, Giovanni, primary, Salido, Marta, primary, Sánchez, Juan, primary, Dalmases, Alba, primary, Bellmunt, Joaquim, primary, De Fabritiis, Gianni, primary, Rovira, Ana, primary, Di Nicolantonio, Federica, primary, Albanell, Joan, primary, Bardelli, Alberto, primary, and Montagut, Clara, primary

Published
2023
Full Text
View/download PDF

49. Figure S2 from KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Author

Misale, Sandra, primary, Fatherree, Jackson P., primary, Cortez, Eliane, primary, Li, Chendi, primary, Bilton, Samantha, primary, Timonina, Daria, primary, Myers, David T., primary, Lee, Dana, primary, Gomez-Caraballo, Maria, primary, Greenberg, Max, primary, Nangia, Varuna, primary, Greninger, Patricia, primary, Egan, Regina K., primary, McClanaghan, Joseph, primary, Stein, Giovanna T., primary, Murchie, Ellen, primary, Zarrinkar, Patrick P., primary, Janes, Matthew R., primary, Li, Lian-Sheng, primary, Liu, Yi, primary, Hata, Aaron N., primary, and Benes, Cyril H., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Tables from KRASG12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

Author

Jones, Gregory D., primary, Caso, Raul, primary, Tan, Kay See, primary, Mastrogiacomo, Brooke, primary, Sanchez-Vega, Francisco, primary, Liu, Yuan, primary, Connolly, James G., primary, Murciano-Goroff, Yonina R., primary, Bott, Matthew J., primary, Adusumilli, Prasad S., primary, Molena, Daniela, primary, Rocco, Gaetano, primary, Rusch, Valerie W., primary, Sihag, Smita, primary, Misale, Sandra, primary, Yaeger, Rona, primary, Drilon, Alexander, primary, Arbour, Kathryn C., primary, Riely, Gregory J., primary, Rosen, Neal, primary, Lito, Piro, primary, Zhang, Haiying, primary, Lyden, David C., primary, Rudin, Charles M., primary, Jones, David R., primary, Li, Bob T., primary, and Isbell, James M., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results